Genetic and process engineering strategies for enhanced recombinant N -glycoprotein production in bacteria by Pratama, Fenryco et al.
Pratama et al. Microb Cell Fact          (2021) 20:198  
https://doi.org/10.1186/s12934-021-01689-x
RESEARCH
Genetic and process engineering strategies 
for enhanced recombinant N-glycoprotein 
production in bacteria
Fenryco Pratama1,2,4, Dennis Linton3 and Neil Dixon1,2*  
Abstract 
Background: The production of N-linked glycoproteins in genetically amenable bacterial hosts offers great poten-
tial for reduced cost, faster/simpler bioprocesses, greater customisation, and utility for distributed manufacturing of 
glycoconjugate vaccines and glycoprotein therapeutics. Efforts to optimize production hosts have included heterolo-
gous expression of glycosylation enzymes, metabolic engineering, use of alternative secretion pathways, and attenu-
ation of gene expression. However, a major bottleneck to enhance glycosylation efficiency, which limits the utility of 
the other improvements, is the impact of target protein sequon accessibility during glycosylation.
Results: Here, we explore a series of genetic and process engineering strategies to increase recombinant N-linked 
glycosylation, mediated by the Campylobacter-derived PglB oligosaccharyltransferase in Escherichia coli. Strategies 
include increasing membrane residency time of the target protein by modifying the cleavage site of its secretion 
signal, and modulating protein folding in the periplasm by use of oxygen limitation or strains with compromised 
oxidoreductase or disulphide-bond isomerase activity. These approaches achieve up to twofold improvement in 
glycosylation efficiency. Furthermore, we also demonstrate that supplementation with the chemical oxidant cystine 
enhances the titre of glycoprotein in an oxidoreductase knockout strain by improving total protein production and 
cell fitness, while at the same time maintaining higher levels of glycosylation efficiency.
Conclusions: In this study, we demonstrate that improved protein glycosylation in the heterologous host could be 
achieved by mimicking the coordination between protein translocation, folding and glycosylation observed in native 
host such as Campylobacter jejuni and mammalian cells. Furthermore, it provides insight into strain engineering and 
bioprocess strategies, to improve glycoprotein yield and titre, and to avoid physiological burden of unfolded protein 
stress upon cell growth. The process and genetic strategies identified herein will inform further optimisation and 
scale-up of heterologous recombinant N-glycoprotein production.
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Background
Attachment of carbohydrates to proteins is the most 
abundant post-translational modification [1–3]. Pro-
tein glycosylation occurs in all Domains of life, and in 
eukaryotes more than half of all proteins are predicted 
to be glycosylated [4, 5]. It generally involves the trans-
fer of glycans onto the amide side chain of asparagine 
(N-linked) or the hydroxyl group of serine or threonine 
(O-linked) amino acid residues. This extra layer of molec-
ular information affects a variety of protein features, 
from structural dynamics such as folding and stability, to 
involvement in complex cellular physiology such as cell 
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Eukaryotes and a small number of bacterial species 
from the epsilon subdivision of the Proteobacteria share 
a homologous process by which they perform N-linked 
protein glycosylation [10]. Both require assembly of a 
glycan on a lipid anchor, known as a lipid-linked oligo-
saccharide (LLO), followed by transfer of the synthesised 
glycan en bloc by an oligosaccharyltransferase (OTase) 
onto the asparagine residue of the acceptor protein. 
However, there are some key variations in reaction com-
ponents and pathway locations (Fig.  1A, B) [11–13]. In 
eukaryotes, N-linked glycosylation is initiated on the 
cytosolic side of the rough endoplasmic reticulum (ER) 
membrane (Fig.  1B). There, glycosyltransferases (GTs) 
assemble a conserved eukaryotic heptasaccharide struc-
ture on a polyprenol diphosphate moiety known as doli-
chol. This LLO is then flipped to the luminal face of the 
ER and a further seven sugars are added by different GTs 
in the ER lumen before the glycan is transferred to the 
target protein by the OTase complex. In prokaryotes, the 
best characterised N-linked glycosylation pathway is pgl 
(protein glycosylation) in the bacterium Campylobacter 
jejuni (Fig. 1A) [11, 14, 15]. In this pathway, a Cj hepta-
saccharide structure is sequentially assembled by specific 
GTs onto an undecaprenol diphosphate lipid carrier on 
the cytosolic face of the inner membrane (IM), flipped 
onto the periplasmic face of the IM, and transferred to 
the target protein. A conserved enzyme in eukaryotic and 
prokaryotic N-linked glycosylation is the OTase, which 
catalyses covalent attachment of the glycan to the accep-
tor sequon of the target protein [16, 17]. The consensus 
acceptor sequon in Archaea and Eukaryota is N-X-S/T 
(X ≠ Proline), while in bacteria, acidic amino acids at the 
-2 position are required (D/E-X1-N-X2-S/T,  X1, 2 ≠ Pro-
line) [18, 19]. Except for some single-celled protists such 
as Leishmania major and Trypanosoma brucei, eukary-
otic OTases are hetero-oligomeric, comprised of seven to 
nine proteins [10, 20]. The catalytic sub-unit of eukary-
otic OTase is STT3 and in mammals two STT3 isoforms 
(STT3A and B) have distinct roles during N-linked glyco-
sylation. The STT3A-dependent complex associates with 
the translocation machinery to optimise co-translational 
glycan transfer to protein, whilst STT3B-dependent gly-
cosylation occurs following translocation [21, 22]. Bacte-
rial N-linked OTases, such as PglB from C. jejuni, consist 
of a single transmembrane protein homologue of eukary-
otic STT3, that can carry out both co- and post-translo-
cational glycosylation [23–26].
Benefiting from improved pharmacological quality, 
about 70% of marketed recombinant human therapeutic 
proteins contain (mostly N-linked) glycans [27–29]. Pro-
duction in mammalian cells, predominantly in the Chi-
nese Hamster Ovary (CHO) cell, enables the coupling 
of complex mammalian glycans to glycoproteins at an 
industrial scale [30, 31]. However, costly manufacturing 
processes, heterogeneous products, and risk of viral con-
tamination remain a significant challenge for production 
in mammalian cell lines [32–34]. As glycosylation is con-
served in all eukaryotic cells, other eukaryotic expression 
systems such as yeast, plant and insect cells have also 
been employed to perform this modification [35, 36]. 
These systems offer the advantage of relatively faster pro-
duction and lower risk of mammalian virus introduction, 
if non-mammalian or non-humanised glycans are accept-
able within the glycoprotein product [37–39]. However, 
the production of protein containing a novel glycan or 
purely heterologous glycoprotein often requires altera-
tion to native pathways which can potentially affect cell 
fitness, as many glycosylation pathways are essential for 
viability in eukaryotic cells [40–42].
Functional transfer of the pgl locus from C. jejuni into 
E. coli, a bacterial workhorse for recombinant protein 
production, opened up a new area of bacterial glycoen-
gineering [15]. Glyco-competent E. coli carrying heter-
ologous protein glycosylation machinery is an attractive 
platform owing to its potential as a non-virulent, rapidly 
growing host, with low fermentation costs [43–45]. From 
an engineering standpoint, the absence of a native protein 
glycosylation pathway in E. coli facilitates rational design 
to introduce orthogonal glycosylation pathways, without 
interference from endogenous GTs, hence leading to the 
production of homogenous products [45, 46]. In addi-
tion, one could expect a minimised effect of glycoengi-
neering on the fitness of E. coli cells, as the host does not 
depend on protein glycosylation for cell viability. Bacte-
rial glycoengineering also benefits from the use of the key 
enzyme Cj PglB OTase, which has been known to have 
relaxed substrate specificities in term of glycans and tar-
get proteins [18, 23, 24, 47]. Transfer of glycans with vari-
ous size and composition has been demonstrated along 
with a wide range of protein recipients spanning from 
bacterial to eukaryotic origin. The only caveat is that the 
glycans require the presence of an acetamido group in 
the reducing-end sugar [47], and the target protein needs 
to contain the sequon in a structurally exposed and flex-
ible region [18, 26]. To date, glyco-competent E. coli has 
been extensively developed in the manufacture of novel 
recombinant bacterial vaccines and glycoconjugates [46, 
48–52]. Further, promising progress has been made to 
engineer glyco-competent E. coli to produce authentic 
mammalian glycans and glycoproteins [53–56], and to 
explore and engineer bacterial OTase with a greater sub-
strate specificity [57–59].
Nevertheless, a common challenge of recombinant 
N-linked glycoprotein production in E. coli is inefficient 
glycosylation [26, 44, 45, 60]. To overcome this challenge 
some strains were improved by eliminating competing 
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Fig. 1 Schematic overview of native N-linked protein glycosylation pathway and proposed strategies in this study to improve sequon accessibility 
of recombinant target protein to PglB during glycosylation in glycoengineered E. coli. N-linked glycosylation in bacteria/C. jejuni (A) compared 
to early-stage of eukaryotic/mammalian N-linked glycosylation pathway (B). A In C. jejuni, undecaprenol-linked glycan is synthesised by 
glycosyltransferases in the cytoplasm, flipped to the periplasm by flippase (PglK), and then transferred co or post-translocationally to a target 
protein by PglB. B In mammalian N-linked glycosylation, dolichol-linked glycan is synthesised both in the cytosol and endoplasmic reticulum (ER) 
lumen, and glycan is transferred co- or post-translocationally (later not shown) by different STT3 isoforms. C, D Two different strategies are proposed 
to enhance heterologous protein glycosylation in E. coli. C Approach based on increasing PglB interaction with target protein in the membrane. 
Increased membrane residence of target protein was achieved by introducing signal peptide mutations with poor processivity or uncleaved 
signal. D Approach based on increasing sequon accessibility of target proteins to PglB via modulation of target protein folding state during or after 
translocation. Using a disulphide-bonded model protein, protein folding and maturation in the periplasm are delayed by producing the protein 
under suboptimal conditions for disulphide formation such as under oxygen-depleted conditions, in the absence of oxidoreductases, or under 
chemical redox treatment. Solid arrow = increased reaction, dashed arrow = reduced reaction
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pathways either in glycan biosynthesis or glycan desti-
nation [61–65]. Other efforts focused on the genomic 
integration and expression of pglB and other glycosyl-
transferases, led to ~ twofold enhancement in glycosyla-
tion efficiency [65–67]. Glycosylation efficiency was also 
increased by both metabolic pathway engineering (1.2- to 
1.8-fold) and process optimisation (1.3- to 1.5-fold) [33, 
43, 68, 69]. Overall, glycosylation efficiency is reported 
to largely depend upon sequon accessibility, and so it is 
essential to understand how the OTase and target pro-
teins interact during co- and post-translocational glyco-
sylation [23–26]. In vitro studies have shown that folded 
protein can be glycosylated more efficiently by PglB 
(~ 15-fold) if the sequon is located on an exposed, flex-
ible and unstructured region [26]. Sequon accessibility 
can also be enhanced in vitro by interfering with protein 
folding or destabilisation [23]. In contrast, coupling of 
glycosylation and the Sec-translocation pathway in E. coli 
improved AcrA and PEB3 glycosylation (two to fourfold) 
[26]. However, glycosylation efficiency of these recombi-
nant targets remained much lower in E. coli compared 
to C. jejuni (up to 15-fold). Under certain fermentation 
conditions previously evaluated, increased glycosylation 
efficiency occurs in parallel with a decrease in protein 
production, rather than an increase in total amount of 
glycoprotein per cell (yield) [48]. Further, these condi-
tions can also lead to growth defects, negatively affecting 
total glycoprotein per culture volume (titre) [48]. So, in 
order to develop alternative genetic and process strate-
gies it is important to evaluate glycoprotein yield and 
titre as well as glycosylation efficiency.
Mammalian STT3A interacts directly with Sec61 trans-
locon complex, thus increasing the local concentration of 
OTase-target protein substrate and allowing rapid recog-
nition of the sequon in relaxed-unfolded regions of the 
protein during translocation before the protein diffuses 
away from the membrane [22]. Moreover, recent stud-
ies demonstrated the presence of an oxidoreductase-like 
protein in the eukaryotic OTase complex—Ost3p/Ost6p 
in yeast or N33/Tusc3 in human STT3A and B contain-
ing OTases. These oxidoreductase-like proteins modu-
late folding of disulphide-containing proteins in the ER 
lumen prior to glycosylation leading to increased sequon 
accessibility [70, 71]. However, to date the involvement of 
folding modulators has not been reported in the bacterial 
N-glycoprotein pathway.
Here, using E. coli as a host, we explored several strate-
gies to maximise N-linked glycosylation including modu-
lation of expression, sequon folding state and accessibility 
of the target protein, in order to increase interaction with 
PglB (Fig.  1C, D). The target proteins selected varied in 
their structure, disulphide-bond content and sequon 
position in order to explore the impact of different 
protein structural contexts upon the strategies employed. 
Our initial study sought to explore the influence of 
modulating target production level upon glycosylation 
efficiency. We next investigated if increasing membrane 
residency time of the target protein, thereby increas-
ing local interaction between OTase PglB and the target 
protein could enhance glycosylation (Fig. 1C). To further 
explore the effect of protein folding modulation on gly-
cosylation, we used model disulphide-bond containing 
proteins (Fig. 1D). These were produced under sub-opti-
mal conditions for disulphide formation, such as under 
oxygen-depleted condition or in the absence of oxidore-
ductase (ΔdsbB or ΔdsbC), in order to mimic the ER 
lumen of eukaryotes. As production of recombinant pro-
tein under sub-optimal conditions can result in reduced 
cell viability and total protein production, we explored 
supplementation with the chemical oxidant cystine to 
recover disulphide bond-containing protein production 
yields in the oxidoreductase mutant (ΔdsbB). The various 
genetic and process conditions presented here demon-
strated enhanced glycosylation efficiency, yield and titre, 
informing potential strategies to improve N-linked glyco-
sylation in E. coli for the production of various disulphide 
containing and non-disulphide target glycoproteins.
Results
Selection of model proteins to assess glycosylation 
efficiency
The four model proteins used in this study, N-glycosylation 
reporter protein NGRP, anti-β-galactosidase single-chain 
Fv scFv13R4 and R4CM, and bovine pancreatic ribonu-
clease RNase A were selected based on their diversity of 
protein structure, disulphide-bond content, and sequon 
location within the protein (Fig. 2A, B). These model pro-
teins have been used previously to study N-linked glyco-
sylation in E. coli [23, 58, 65, 72]. For simplicity all were 
modified by the addition of a single bacterial N-linked 
glycosylation sequon to assess glycosylation efficiency. 
A C-terminal hexahistidine tag was also added for detec-
tion of glycosylated and non-glycosylated forms by immu-
noblotting (anti-His). NGRP is a truncated version of the 
native periplasmic C. jejuni Cj0114 protein [73] designed to 
improve the performance of glycopeptide structural char-
acterisation by mass spectrometry [58]. NGRP contains 
either a sequon within the C-terminal region and lacks 
disulphide-bonds (Fig.  2A, B, i). The scFv13R4 protein 
was modified by addition of a C-terminal DQNAT glyco-
sylation sequon (Fig. 2B, ii). This sequon was repositioned 
closer to the cysteine residue involved in disulphide-bond 
formation to generate the R4CM variant (Fig. 2A ii, B iii). 
RNase A was modified to replace S32 with D converting 
the nearby native eukaryotic sequon (NLT) to the bacte-
rial consensus sequon (DRNLT) [23]. This sequon is also 
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adjacent to a cysteine residue involved in disulphide-bond 
formation (Fig.  2A iii, B iv). Varying the location of this 
sequon has been shown to influence glycosylation [23, 72]. 
scFv13R4 and R4CM are predicted to have a single disul-
phide-bond [74] whilst RNase A contains four, three of 
which are non-consecutive.
Expression attenuation of the NGRP model target 
has limited impact upon glycosylation efficiency
It was previously shown that NGRP was produced in E. 
coli as a soluble periplasmic protein [58]. Initially in this 
study, we aimed to explore the impact of NGRP expres-
sion level upon glycosylation efficiency using inducible 
expression vector pDEST-ORS (Fig. 3A). In this vector, 
expression of the target gene is regulated both tran-
scriptionally by the IPTG-inducible tac promoter  (Ptac) 
and translationally by the PPDA-inducible orthogonal 
riboswitch (ORS) located within the 5ʹ UTR [75, 76]. 
The SecB-dependent signal peptide of PelB was inte-
grated at the N-terminus of the target protein to direct 
secretion into the periplasm. The 5ʹ coding sequence 
context of genes has previously been shown to influence 
riboswitch conformation and gene expression levels 
[77]. Here, three variants containing different synony-
mous codons at the first eight amino acids within the 
PelB leader sequence were used, termed wild type 
(WT), PelB 1 and PelB 2-NGRP (Fig. 3A). pDEST-ORS-
NGRP was transformed into E. coli Top10F’ expressing 
Fig. 2 Structural variation of model glycoproteins. A Structural models of (i) NGRP, (ii) scFv13R4 and scFv13R4CM were generated by Phyre2 based 
on protein homology prediction (≥ 99% confidence) [113]. (iii) X-ray crystallographic structure of RNase A (PDB code 3WMR). Ribbon model of the 
proteins was drawn by UCSF Chimera [114]. Position of the sequon variants (D/E-X-N-X-S/T, X ≠ P) within the protein is indicated. Disulphide-bonds 
are highlighted in yellow. C-terminal sequon (DQNAT) of scFv13R4 is not displayed in the protein model. B Linear representation of proteins; (i) 
NGRP, (ii) scFv13R4, (iii) scFv13R4CM, and (iv) RNase A. Position of disulphide-bonds (C–C) and glycosylation sites (N) are indicated with amino acid 
positions
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the C. jejuni N-glycosylation machinery from pACYC 
pgl (glyco-competent). Cells were cultivated in tripli-
cate and expression induced over a range of different 
inducer concentrations (100  μM IPTG and 0, 2, 8, 40, 
100, 200 and 400  μM PPDA) (“Methods” section). To 
analyse glycoprotein production, proteins were col-
lected from periplasmic fractions. Total target protein 
was quantified by Western blot densitometry in which 
pre-determined purified protein (between 15 to 100 ng) 
was used as a standard for quantification (“Methods” 
section). The quantification data were plotted as the 
yield mg/g of dry cell weight (DCW) following the 
normalisation and conversion of measured  OD600 into 
DCW (“Methods” section). Glycosylation efficiency (%) 
was determined from the proportion of glycosylated to 
total NGRP  (G1/G1 +  G0). NGRP expression in glyco-
competent E. coli produced a single band indicative of 
glycosylated NGRP (~ 22 kDa) with slower migration in 
Fig. 3 Glycosylation of NGRP in glyco-competent E. coli. A Organisation of pDEST-ORS expression vector used in this study. Target gene (NGRP) was 
fused with Sec signal peptide PelB (N-terminal) and Hexahistidine-tag (C-terminal). Expression of the target gene was regulated transcriptionally 
by  Ptac via IPTG induction and translationally by orthogonal riboswitch (ORS) via PPDA titration. IPTG = Isopropyl β-d-1-thiogalactopyranoside, 
PPDA = Pyrimido [4,5-d] pyrimidine-2,4-diamine. Three synonymous nucleotide sequence variants of PelB-NGRP N-terminal codon (PelB 1, PelB 2, 
and PelB WT or wild-type) are shown. These variants were tested to explore the impact of the 5ʹ codon context upon the riboswitch-dependent 
regulatory function. B Western blot analysis of periplasmic fractions of glyco-competent (GC) and non-glycocompetent (Non-GC) strains of E. coli. 
Anti-His antibody was used to detect the NGRP. Arrows indicate non-glycosylated  (G0) and glycosylated  (G1) NGRP. C, D Quantitative Western blot 
analysis (Densitometry) of NGRP located in the periplasmic fractions from the two signal peptide variants, C PelB 1 and D PelB 2-NGRP. Proteins were 
produced with increasing PPDA inducer concentrations (100 μM IPTG and 0, 2, 8, 40, 100, 200, 400 μM PPDA). Total proteins were quantified using 
a pre-determined purified NGRP standard curve (15 ng to 100 ng) (“Methods”). The data were converted into mg/g of dry cell weight (DCW) based 
on normalisation and calculation with measured  OD600 of the samples. Glycosylated (yellow bar) and non-glycosylated (green bar) protein are as 
shown (left y-axis). % Glycosylation (%  G1/G0 +  G1) is indicated (black circle, right y-axis). Data were processed from three biological replicates; error 
bars represent standard deviation from mean values. Representative Western blots are shown as insets
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the gel compared to non-glycosylated NGRP (~ 20 kDa) 
(Fig.  3B). Previous study has confirmed by mass spec-
trometry that this altered mobility of NGRP is due to 
N-linked glycosylation [58].
For all constructs no NGRP production was detected 
in the absence of inducer confirming tight control of 
basal expression (Additional file 1: Figure S1A). Produc-
tion of NGRP containing PelB-WT showed poor titrat-
ability upon induction (Additional file 1: Figure S1B–D) 
but titration of NGRP production was observed with 
increasing PPDA inducer in PelB 1 and PelB 2-NGRP 
constructs giving a dynamic range of expression of 
6 and 15-fold respectively (expression level at Max/
Min inducer concentration) (Fig.  3C, D). Interest-
ingly, NGRP was glycosylated with similar efficiency 
(PelB 1-NGRP = 45 ± 4%, PelB 2-NGRP = 49 ± 5%) 
irrespective of the total amount of NGRP produced 
(PelB 1-NGRP = 3.9 ± 0.9 to 22.7 ± 1.5  mg/g DCW, 
PelB 2-NGRP = 1.2 ± 0.4 to 17.7 ± 1.5  mg/g DCW) 
(Fig. 3C, D). Correlation analysis (Pearson) showed no 
strong or significant relationship between glycosylation 
efficiency and the protein production level of NGRP 
(Additional file  1: Figure S2). This appears to indicate 
that the cell glycosylation capacity i.e., lipid-glycan 
substrate availability and glycosylation enzyme activ-
ity do not limit NGRP glycosylation, at least within 
the parameters of this experiment. Cell growth was 
analysed based on the optical density of cell culture at 
the end of incubation or induction. The result showed 
that increased NGRP production level has minimal but 
significant impact on cell growth (Pearson correlation 
PelB 1-NGRP, r = − 0.7645, P = 0.0453 PelB 2-NGRP, 
r = − 0.8042, P = 0.0292) (Additional file  1: Figure S3). 
As the PelB 1 variant of leader sequence gave highest 
maximum expression and improved dynamic range of 
gene expression, this variant then was used within the 
pDEST-ORS construct for the subsequent experiments.
Design of a signal peptide cleavage site mutant 
to increase membrane residency time of target protein 
during glycosylation
As the gene titration analysis of NGRP indicated that gly-
cosylation efficiency was independent of the amount of 
protein produced, we sought to explore if glycosylation 
efficiency was dependent upon the target protein resi-
dency time within the membrane, and therefore whether 
co-translocational glycosylation could be enhanced. To 
do this we constructed a system to allow membrane trap-
ping of the target protein through modification of the 
PelB signal peptide cleavage site. We reasoned that by 
decreasing the recognition and processivity of the cleav-
age site by signal peptidase I (SPaseI) (Additional file  1: 
Figure S4), that the target protein would be trapped in the 
membrane leading to increased residency time between 
the OTase and the target protein-Sec complex. In addi-
tion to NGRP, we also used scFv13R4 as a target protein, 
to explore how the strategy would work with structurally 
distinct proteins.
The SPaseI-dependent cleavage site is located at the C 
terminal end of the signal peptide after the recognition 
motif Ala-X-Ala (X any amino acids) (Additional file  1: 
Figure S4) [78]. Substituting Ala with Thr at -1 from the 
cutting site has been shown to reduce processing [78, 
79]. Another key amino acid is a proline residue around 
− 4 to − 6, whose structural turn promotes signal pep-
tide alignment with SPaseI, and deletion or replacement 
is reported to inhibit signal peptide cleavage [79, 80]. In 
silico analysis (SignalP 4.1) of the resultant modified PelB 
signal peptide Leu-Thr-Met-Thr (TMT) motif showed 
a predicted 40–60% decrease in cleavage site process-
ing compared to the wild type Pro-Ala-Met-Ala (wt) 
motif (Additional file 1: Figure S5A-B and C-D, table for 
Y-score) [81]. With only residues around the cleavage site 
modified in the TMT variant, 90% of Sec signal sequence 
was left unchanged (N, H and C-region) [82], retaining 
the signal for protein sorting and delivery to the translo-
con (Additional file 1: Figures S4, S5). PCR site-directed 
mutagenesis then was performed to generate a TMT 
mutant of PelB NGRP and scFv13R4 in the pDEST-ORS 
construct (“Methods” section).
To investigate the effect of the cleavage site mutations 
upon protein localisation and glycosylation, NGRP and 
scFv13R4 wt and TMT variants were expressed in glyco-
competent (GC) and non glyco-competent (Non-GC, 
control) E. coli strains (“Methods” section). We hypoth-
esised there would be four possible NGRP or scFv13R4 
isoforms generated based on their signal peptide proces-
sivity and glycosylation state (Fig.  4A). These predicted 
forms were processed (a-form), unprocessed (b-form), 
processed glycosylated (c-form), and unprocessed glyco-
sylated (d-form). Glycosylated and unprocessed protein 
will migrate slower than non-glycosylated and processed 
protein due to additional glycan (single, ~ 1.5  kDa) and 
un-cleaved signal peptide (~ 2  kDa). As expected, the 
fastest migrating species were observed in the periplasm, 
(Fig. 4B, C, lanes 1 and 5), and are predicted to be cor-
rectly processed (a-form). In contrast, the mutated sig-
nal peptide cleavage site clearly impacts upon the release 
of target protein into the periplasm fraction (Fig. 4B, C, 
lanes 3 and 7). Further, proteins with the TMT mutation 
were only observed located in the membrane fraction 
(Fig. 4B, C, lanes 4 and 8), which are most likely unpro-
cessed (b-form). Glycosylated isoforms were observed as 
an additional higher molecular weight band in the peri-
plasm or membrane of glyco-competent cell (predicted c 
or d-form) (Fig.  4B, lanes 5 and 8, and Fig. 4C, lanes 5, 
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6 and 8). Glycosylation was confirmed using a polyclonal 
CjNgp antiserum [83] but as it detects both glycosylated 
and non-glycosylated NGRP (Additional file 1: Figure S6) 
it could not be used to probe the degree of glycosylation 
in NGRP. However, the glycosylation status of scFv13R4 
could be clearly observed (Fig.  4C). We noticed that 
the gel migration of some predicted isoforms could not 
be clearly resolved or with apparent different migration 
across the different lanes of the gel, (e.g., Fig. 4B, lanes 5, 
6 and 8, and Fig. 4C, lanes 5 and 8). To rule out that band 
separation was due to differences in migration in differ-
ent gel lanes, we mixed the samples (lane 5 and 8) and 
ran them together for an extended electrophoresis run-
ning time. By this re-running, all 4 isoforms (a–d forms) 
were detected as expected and the difference in migration 
rate was evident (Additional file 1: Figure S8). No glyco-
sylated isoforms were observed in the non glyco-compe-
tent controls (Fig. 4B, C, lanes 1–4). Although analysis of 
the membrane fraction from both glyco-competent and 
noncompetent cells producing scFv13R4 with the wt sig-
nal peptide cleavage site produced bands (Fig. 4C, lanes 
2 & 6) with similar migration as those in the periplasm 
fractions (a-form) (Fig. 4C, lanes 1 and 5). However, we 
suspect this band is correctly processed but insoluble 
scFv13R4 from the periplasm that has been associated 
with the membrane during the fractionation process, 
indeed this observation has been previously reported for 
this protein [76].
Fig. 4 Production of NGRP and scFv13R4 isoforms containing signal peptide cleavage site variants. A Schematic representation of four predicted 
isoforms of NGRP or scFv13R4 (a-d-forms) based on their signal peptide processivity and protein glycosylation. B, C Western blot analysis 
of membrane (M) and periplasmic (P) expression of wild type (wt) and signal peptide cleavage mutant (TMT) NGRP (B) and scFv13R4 (C) in 
glyco-competent (GC) and non glyco-competent (Non-GC) E. coli. B, C All NGRP and scFv13R4 isoforms were detected by anti-His antibody. 
Glycosylated scFv13R4 was detected by CjNgp antibodies. Predicted a-d isoforms within the bands are indicated. The lanes in panel B are from the 
same blot while white vertical lines indicates a non-adjacent lanes. The protein migration band relative to each other in different lanes in the blot 
is unchanged. Additional file 1: Figure S7 shows the uncropped Western blot image of B. D–G Quantitative Western blot analysis (Densitometry) of 
membrane (TMT) and periplasmic (wt) localised D–E NGRP and F–G scFv13R4 produced in glyco-competent E. coli. Proteins were produced under 
different induction conditions (100 μM IPTG and 0, 8, 40 and 200 μM PPDA). Anti-His antibody was used to detect the proteins (glycosylated and 
non-glycosylated). Total proteins were quantified using a pre-determined purified NGRP or scFv13R4 standard curve (5 ng to 100 ng) (“Methods”). 
The data were converted into mg/g of dry cell weight (DCW) based on normalisation and calculation with measured  OD600 of the samples. 
Glycosylated (yellow bar) and non-glycosylated (green bar) protein as shown (left y-axis). % Glycosylation (%  G1/G0 +  G1) is indicated (black circle, 
right y-axis). All data (D–G) were processed from three biological replicates. Error bars indicate standard deviation from mean values
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In agreement with previous findings, the ability of 
PglB to perform co-translocational glycosylation was 
supported here by observation of glycosylated pre-pro-
tein TMT-NGRP and TMT-scFv13R4 (d-form) in the 
membrane of glyco-competent cells (Fig. 4B, C, lanes 8) 
[26]. Whereas wt-NGRP seems to be glycosylated post-
translocation or just before the protein release into the 
periplasm after signal peptide processing, since no glyco-
sylation of the membrane bound wt-NGRP pre-protein 
(d-form) was detected (Fig. 4B, lane 6). Glycosylation of 
membrane bound NGRP was only observed for the TMT 
variant where an additional band in the membrane was 
shown, suggesting that glycan is mostly acquired dur-
ing an extended residency time within the membrane 
(Fig.  4B, lane 8). In subsequent experiments, we per-
formed quantitative analysis of glycosylation efficiency 
for the target proteins in both the membrane and in the 
periplasm.
Glycosylation of NGRP and scFv13R4 during extended 
membrane residency time
Our data demonstrated that target proteins containing 
the modified cleavage site (TMT) were not released to the 
periplasm and were retained in the membrane. To evalu-
ate how secretion attenuation contributed to glycosyla-
tion, the wt and TMT variants of NGRP and scFv13R4 
were produced in glyco-competent E. coli, under differ-
ent inducer concentrations (100  μM IPTG and 0, 8, 40, 
200 μM PPDA) (“Methods” section). Figure 4D–G shows 
the quantitative Western blot analysis of protein detected 
in the periplasm and membrane fractions for the wt and 
TMT variants. We observed that total target protein pro-
duction increased upon induction, but with only modest 
dynamic ranges observed for scFv13R4 (wt = 1.6-fold, 
from 7.5 ± 2.3 to 12.3 ± 3.8  mg/g DCW; TMT = 1.4-
fold, from 0.39 ± 0.07 to 0.56 ± 0.17 mg/g DCW) in con-
trast to NGRP which displayed greater dynamic ranges 
(wt = 4.3-fold, from 3.3 ± 0.7 to 11.7 ± 0.6  mg/g DCW; 
TMT = 2.4-fold, from 4.7 ± 0.5 to 10.1 ± 0.9 mg/g DCW). 
Both membrane (TMT) and periplasmic (wt) fractions of 
NGRP yielded similar amounts of target protein under 
the same induction condition (Fig.  4D, E; Additional 
file  1: Figure S9A). In contrast, the membrane fraction 
for TMT-scFv13R4 had significantly lower target pro-
tein than the periplasmic fraction wt-scFv13R4 (~ 15- to 
20-fold reduction) (Fig.  4F, G; Additional file  1: Figure 
S9B). One possible explanation is that the two exemplar 
target proteins display different intrinsic stability and 
proteolytic susceptibility within the membrane, which 
consequentially reduces the relative protein yield in the 
membrane compared to that observed in the periplasm 
fraction. As previously observed (Fig. 3C, D), the propor-
tion of glycosylated NGRP was minimally impacted by 
the protein production levels, both in the periplasm frac-
tion (wt) and in the membrane fraction (TMT) (average 
glycosylation efficiency wt = 29 ± 6%, TMT = 31 ± 3%) 
(Fig. 4D, E). Indeed, correlation analysis (Pearson) showed 
no significant relationship between protein level and gly-
cosylation efficiency for wt and TMT-NGRP (Additional 
file  1: Figure S10A and B). Increased NGRP production 
levels had no negative impact upon cell growth at lower 
induction condition (0–40  μM PPDA)  (OD600 wt ~ 8, 
TMT ~ 11) (Additional file 1: Figure S11A, B). Only at the 
highest induction levels (200 μM PPDA), was a reduction 
in cell growth observed  (OD600 wt ~ 5, TMT ~ 3) (Addi-
tional file 1: Figure S11A, B). Overall, we did observe cell 
culture dependent effects, as lower NGRP glycosylation 
efficiency and protein yields were achieved in this experi-
ment (Fig.  4) compared to the previous result (Fig.  3) 
(glycosylation efficiency mean 45 ± 4% vs 29 ± 6%, and 
total yield 23.94 ± 2.21 vs 11.7 ± 0.6  mg/g DCW). The 
previous experiment was run under microculture cultiva-
tion conditions (vs. flask) and shorter induction time (3 h 
vs 6 h) (see “Methods” section).
In contrast to the limited impact of titration upon gly-
cosylation efficiency for NGRP, increased scFv13R4 pro-
duction levels led to decreased glycosylation efficiency 
(wt = 1.6-fold, from 96 to 63%; TMT = 1.4-fold, from 
77 to 47%) (Fig.  4F, G). Correlation analysis (Pearson) 
showed a significant inverse relationship between pro-
tein expression level and glycosylation efficiency for wt-
scFv13R4 (r = − 0.9920, P = 0.008), while for TMT no 
significant correlation was observed) (Additional file  1: 
Figure S10C, D). Cell growth analysis showed that pro-
duction of both the scFv13R4 variants (wt and TMT) led 
to reduced cell growth at higher protein production lev-
els (wt  OD600 5.4 ± 0.2 to 2.4 ± 0.6; TMT  OD600 3.0 ± 0.5 
to 2.1 ± 0.2) (Additional file  1: Figure S11C, D). There-
fore, in addition to the effect of protein production level, 
reduced cell fitness could also possibly contribute to the 
decreasing glycosylation activity in the cell [48].
Interestingly, glycosylation efficiency of the mem-
brane-bound TMT-scFv13R4 was always consistently 
higher than for the periplasmic wt-scFV13R4 under 
the same induction conditions (96–63% vs 77–47%, 
0.015 ≤ P ≤ 0.08) (Fig.  4, F and G, and Additional file  1: 
Figure S12A). Whereas the glycosylation efficiency 
observed for the NGRP variants was similar under the 
same induction conditions (0–40 μM PPDA, wt 34%–28% 
vs. TMT 34%–29%). The exception to this observed trend 
was under the highest induction conditions (200  μM 
PPDA) which showed lower glycosylation efficiency 
of wt-NGRP (22%) compared to TMT-NGRP (29%) 
(Fig. 4D, E, and Additional file 1: Figure S12B). The lower 
production level of TMT-scFv13R4, when compared 
to the wt-scFv13R4, is a potential contributing factor to 
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the observed increase glycosylation efficiency. However, 
analysis of the relationship between protein yield and 
glycosylation efficiency for wt-scFv13R4 by linear regres-
sion (Additional file 1: Figure S13), indicates that at lower 
protein production levels (≤ 4.15  mg/g DCW) the tar-
get protein would be predicted to be fully glycosylated. 
Therefore, it would be expected that TMT-scFv13R4 
would be fully glycosylated at the yields observed in the 
membrane (from 0.39 ± 0.07 to 0.56 ± 0.17 mg/g DCW). 
Therefore, protein production levels alone are likely not 
the only factor that can affect TMT-scFv13R4 glycosyla-
tion, and other factors, such as sequon accessibility dur-
ing membrane retention could limit glycosylation. From 
this analysis it is clear that protein glycosylation is a com-
bination of glycosylation both during protein transloca-
tion through the membrane (co-translocation) and after 
translocation in the periplasm (post-translocation). So, 
to achieve maximal glycosylation efficiency optimal con-
ditions for both processes are required. Therefore, the 
extended membrane residency time of the TMT variant 
compared to the wt, appears to be a likely contributing 
factor upon the observed increase in glycosylation.
Increased glycosylation efficiency of membrane-bound 
scFv13R4-TMT indicated that extended membrane 
residency time may enhance protein glycosylation com-
pared to the when protein is released into the periplasm 
(scFv13R4-wt). However, since glycosylation efficiency of 
NGRP was not affected by enhanced membrane reten-
tion, we suspected that the structural context of the 
sequon within NGRP and scFv13R4 influences their 
respective abilities to accept glycan from PglB. Unlike 
NGRP, scFv13R4 contains disulphide-bonds, formation 
of which are important for correct protein folding and 
which might be impeded by membrane retention [84, 
85]. Indeed, the different effects of membrane retention 
upon protein folding and stability of NGRP and scFv13R4 
might also influence the different protein yields observed 
between periplasmic (wt) and membrane production 
(TMT) of both proteins (Fig.  4D–G). Additionally, hav-
ing more complex secondary and tertiary structure than 
NGRP, scFv13R4 might require longer time to fold which 
consequently may extend the unfolded glycosylation-
competent state in the membrane [85]. If formation of 
structural elements (e.g., disulphide-bonds) in the target 
protein could be impeded to modulate protein folding 
and glycosylation, we hypothesised that perhaps specific 
conditions that impede structure formation could also 
be exploited to enhance protein glycosylation. Thus, we 
explored the impact of varying both genetic and process 
(growth) conditions that might lead to attenuation of 
disulphide-bond formation, to improve production of the 
target recombinant glycoprotein.
Expressing disulphide‑bond containing proteins 
under oxygen‑depleted condition enhances glycosylation 
efficiency
Intramolecular disulphide-bonds are essential to main-
tain the folding and stability of many proteins [86]. In E. 
coli and many Gram-negative bacteria, their formation 
is catalysed enzymatically by the dedicated disulphide-
bond forming (DSB) pathway, primarily under aerobic 
conditions [87–90]. The key enzymes in this pathway are 
the periplasmic thioredoxin-like protein DsbA and the 
transmembrane recycling factor protein DsbB. DsbA oxi-
dises protein substrates to give rise to a disulphide-bond, 
whilst reduced DsbA is quickly recycled to its active oxi-
dised form by DsbB. DsbB is then re-oxidised by ubiqui-
none via the electron transport chain, in which the final 
electron acceptor is oxygen during aerobic growth [90]. 
However, during growth in low oxygen or anaerobic con-
ditions, menaquinone mediates the transfer of electrons 
to alternative acceptors such as nitrate or small organic 
molecules such as fumarate. This leads to a reduced oxi-
dation rate for both DsbAB relative to the aerobic path-
way [87, 88].
Here we varied oxygen availability to modulate disul-
phide-bond formation and protein folding and moni-
tored consequent protein glycosylation levels. To vary 
the oxygen transfer to cells in liquid media, cultures were 
grown in shake flasks with different culture to flask vol-
ume ratios (5:50, 10:50, and 25:50  ml) (“Methods” sec-
tion). As described scFv13R4, scFv13R4CM, and also 
RNase A were modified with glycosylation sequons and 
used as the target disulphide-bond containing proteins 
and NGRP (DQNAT) acted as a non-disulphide bond 
containing control protein.
A modest but significant increase in glycosylation effi-
ciency was observed when disulphide-bond contain-
ing proteins were produced in higher culture to flask 
volume ratio (5:50 to 25:50  ml; scFv13R4 62 to 79%, 
P = 0.005; scFv13R4CM 41 to 52%, P = 0.028; RNase A 
20 to 34%, P = 0.017) (Fig.  5A–C). A rise in glycosyla-
tion efficiency was also examined for the control NGRP 
when the cells were grown at higher culture to flask 
volume ratio (5:50 to 10:50  ml, 25% to 40%, P = 0.004) 
(Fig.  5D). However, in contrast to the trend observed 
for disulphide bond-containing proteins, NGRP glyco-
sylation efficiency decreased when the cells were grown 
at the highest culture to flask volume ratio (10:50 to 
25:50 ml, 40% to 26%, P = 0.017—Fig. 5D). Each protein 
was produced at generally similar levels in these differ-
ent conditions (mean yield scFv13R4 = 4.7 ± 1.0  mg/g 
DCW, scFv13R4CM = 4.8 ± 0.6  mg/g DCW, RNase 
A = 2.9 ± 0.6 mg/g DCW, NGRP = 4.0 ± 0.8 mg/g DCW). 
scFv13R4 protein production saw a small, but not signifi-
cant, decrease at higher culture ratios (1.3-fold, 5:50 to 
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25:50), and RNase A also saw a small, but not significant, 
increase (1.3-fold, 5:50 to 25:50) (Fig. 5A, C). In addition, 
correlation analysis (Pearson) showed that the change in 
glycosylation efficiency was not significantly associated 
with the production level of disulphide-bond proteins 
during growth in different culture to flask volume ratio 
(Additional file 1: Figure S14).
In order to further explore the effect of lower oxygen 
culture conditions upon protein glycosylation, cells were 
grown in a hypoxic chamber with 3% (hypoxic) or 15% 
 O2 (normoxic) (“Methods” section). Production under 
hypoxic conditions also increased glycosylation efficiency 
of disulphide bond-containing proteins, however only 
scFv13R4CM showed a significant change (15% to 3%  O2; 
% glycosylation scFv13R4 73% to 82%, scFv13R4CM 51% 
to 61% P = 0.027, RNase A 26% to 32%, NGRP 30% to 
28%), which may also be attributed to the observed greater 
reduction in scFv13R4CM protein yield (scFv13R4CM 
from 5.9 ± 0.9 to 2.9 ± 0.5 mg/g DCW, P = 0.005) (Fig. 5E–
H). To test if glycosylation of disulphide bond-containing 
proteins was more sensitive to the change in oxygen levels 
compared to glycosylation of non-disulphide bond-con-
taining proteins (NGRP), we quantified the fold-change of 
glycosylation between the proteins expressed in hypoxic 
(treatment) and normoxic (control) conditions. This fold-
change is defined as relative glycosylation efficiency (RGE) 
was calculated as follows:
Therefore, even if glycosylation of non-disulphide 
bond-containing protein were to change in a similar 
direction as the model disulphide bond-containing pro-
tein, the degree of change could be compared using the 
RGE metric. The RGE results showed that disulphide 
bond-containing proteins experienced a modest increase 
in glycosylation fold-change during hypoxic treatment 
(scFv13R4 1.1-fold, scFv13R4CM 1.2-fold, RNase A 1.3-
fold) but this was significantly different to the change in 
glycosylation observed for NGRP under the same con-
ditions (0.92-fold) (P = 2.0 ×  10–4, 3.3 ×  10–6, 8.3 ×  10–5 
respectively) (Additional file 1: Figure S15).
While the glycosylation efficiency of disulphide bond-
containing proteins increased when produced under 
oxygen-depleted conditions, cell growth was also dra-
matically reduced (Table  1). The negative impact upon 
RGE =
(
Glycosylation efficiency under treatment (G1/G1 + G0)
Glycosylation efficiency of the control (G1/G1 + G0)
)
Fig. 5 Effect of culture conditions and oxygen availability upon target protein glycosylation in E. coli. A–D Effect of culture to flask volume 
ratio (oxygen transfer efficiency) upon target protein glycosylation in E. coli. Quantitative Western blot analysis (densitometry) of A scFv13R4, 
B scFv13R4CM, C RNase A and D non-disulphide control protein NGRP located in periplasm of glyco-competent E. coli in shake flask under 
three different cultures to flask volume ratio (5:50, 10:50, and 25:50 ml). E–H Quantitative Western blot analysis (densitometry) of E scFv13R4, 
F scFv13R4CM, G RNase A and H NGRP control non-disulphide bond-containing protein, detected in the periplasm of glyco-competent E. coli 
under different oxygen levels culture (3% and 15%  O2). A–H Total proteins were quantified using pre-determined purified scFv13R4CM, RNase, or 
NGRP standard curve (5 ng to 100 ng). The data were converted into mg/g of dry cell weight (DCW) based on normalisation and calculation with 
measured  OD600 of the samples. A–H Glycosylated (yellow bar) and non-glycosylated (green bar) protein as shown (left y-axis). % Glycosylation (% 
 G1/G0 +  G1) is indicated (black circle, right y-axis). Statistical analysis was conducted by unpaired t-test with Welch’s correction to control sample at 
lowest culture to flask volume ratio 5:50 (A–D) or to control normoxic culture (E–H) (P < 0.05*, < 0.01**, for % glycosylation; P < 0.05◊, for total protein 
mg/g DCW). All data were processed from three biological replicates. Error bars indicate standard deviation from mean values
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growth seems independent of target protein and most 
likely related to cellular oxygen requirements, since both 
cells expressing disulphide or non-disulphide bond-
containing proteins were negatively affected. Volumetric 
production (titre) of recombinant protein was decreased 
as a result of reduced cell growth during production in 
oxygen depleted conditions (Table 1).
Production and glycosylation of disulphide 
bond‑containing proteins in the absence 
of oxidoreductase DsbB
Studies have shown that in the absence of DsbA or DsbB, 
in order to maintain cell viability and disulphide-bond 
formation either additional oxygen or media supple-
mentation with a strong oxidant is required [91]. Nev-
ertheless, the rate of disulphide-bond formation driven 
directly by oxygen supplementation in these knockout 
strains does not fully rescue the reaction catalysed by the 
DSB pathway [88, 91]. The previous experiments dem-
onstrated that producing disulphide bond-containing 
proteins under suboptimal conditions for disulphide-
bond formation might delay protein folding, leading to 
enhanced interaction time with OTase and the sequon, 
and greater glycan transfer. Therefore, we hypothesised 
that when disulphide bond-containing proteins were 
produced in glyco-competent E. coli lacking one of 
DsbAB enzymes, such as in the ΔdsbB strain, glycosyla-
tion would be enhanced. To test this, a glyco-competent 
ΔdsbB strain was transformed with expression vectors 
encoding the model disulphide bond-containing proteins 
and control NGRP, and glycosylation analysed following 
standard shake flask cultivation (“Methods” section).
Densitometric analysis of periplasmic proteins dem-
onstrated increased glycosylation efficiency of scFv13R4 
and scFv13R4CM in the ΔdsbB strain compared to the 
wild-type (wt) strain (scFv13R4 73% to 88%, P = 0.047; 
scFv13R4CM 50% to 80%, P = 1.1 ×  10–4) (Fig.  6A, B). 
However, expression in the ΔdsbB strain showed a nega-
tive effect for glycosylation of RNase A (25% to 10%, 
P = 0.025) (Fig.  6C). In parallel a significant reduction 
in protein production (50–90%) was observed for all 
three disulphide-containing model proteins in ΔdsbB 
relative to the wt strain (scFv13R4 from 3.5 ± 0.4 to 
1.0 ± 0.3  mg/g DCW, P = 1.7 ×  10–3; scFv13R4CM from 
5.0 ± 0.6 to 2.7 ± 0.2 mg/g DCW, P = 1.4 ×  10–2; RNase A 
from 3.0 ± 0.1 to 0.24 ± 0.05 mg/g DCW, P = 5.9 ×  10–7). 
We suspected that the proteins might be prone to deg-
radation following an extended delay in disulphide-bond 
formation and protein folding in the absence of the DsbB 
enzyme [89, 90]. Indeed, consistent with this notion, 
RNase A production was most severely affected since it 
has four disulphide-bonds compared to one for scFv13R4 
and scFv13R4CM (Fig.  2A ii–iii and B ii–iv). However, 
as glycosylation efficiency can be impacted by lower 
amounts of target protein substrate, increased glycosyla-
tion efficiency of scFv13R4 and scFv13R4CM cannot be 
attributed solely to the delay of disulphide-bond forma-
tion during expression in the ΔdsbB strain. No signifi-
cant change in total protein and glycosylation efficiency 
of control NGRP was observed in the ΔdsbB strain in 
Table 1 Comparative cell growth and volumetric productivity (protein titre) during recombinant disulphide-bond protein production 
in oxygen-depleted conditions
a Final cell density was measured as  Abs600 (Final  OD600) recorded 4 h after induction
b Total protein titre was determined from the Western blot quantification data (glycosylated and non-glycosylated), normalised and converted from sample  OD600 of 
periplasmic fraction and sample volume for Western blot. For the final cell density and protein titre, the average of three biological replicates is shown and the errors 
indicate standard deviation
c 5, 10, and 25 ml of cell culture were grown in 50 ml shake flask to have culture with different culture to flask volume ratio
d Variation in oxygen level was performed by growing the cells in 24-well plate incubated in hypoxic chamber exposed to 3%  O2 (hypoxic) or 15%  O2 (normoxic). The 
change (increasing or decreasing) of cell growth and protein titre relative to control (cell cultivation under more oxygenated conditions, 5/50 culture to flask volume 
ratio or 15%  O2) was analysed by t-test with Welch’s correction (Additional file 2: Table S2 and S3)
Proteins Cell  growtha and protein  titreb
Culture to flask volume ratio (Oxygen transfer) Oxygen level
5:50c 10:50 25:50 15%d 3%
scFv13R4 5.49 ± 0.05 4.35 ± 0.17 2.85 ± 0.05 5.57 ± 0.09 2.43 ± 0.05
10.78 ± 2.37 mg/L 6.30 ± 0.63 mg/L 4.25 ± 0.49 mg/L 10.40 ± 1.39 mg/L 3.59. ± 0.45 mg/L
scFv13R4CM 5.01 ± 0.12 4.13 ± 0.09 2.83 ± 0.13 4.43 ± 0.05 2.34 ± 0.05
8.29 ± 0.76 mg/L 7.13 ± 1.01 mg/L 4.72 ± 0.88 mg/L 9.15 ± 1.39 mg/L 2.35 ± 0.40 mg/L
RNase A 3.65 ± 0.09 2.56 ± 0.00 1.84 ± 0.08 2.93 ± 0.05 1.92 ± 0.00
3.24 ± 0.49 mg/L 3.14 ± 0.50 mg/L 2.27 ± 0.29 mg/L 4.55 ± 0.60 mg/L 2.63 ± 0.41 mg/L
NGRP 8.87 ± 0.46 5.33 ± 0.17 3.31 ± 0.09 4.83 ± 0.17 2.51 ± 0.05
12.65 ± 2.11 mg/L 8.83 ± 0.40 mg/L 3.66 ± 0.78 mg/L 5.88 ± 1.40 mg/L 2.99 ± 0.52 mg/L
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comparison to the wt strain (wt = 8.5 ± 1.4  mg/g DCW, 
ΔdsbB = 7.2 ± 1.2 mg/g DCW) (Fig. 6D). The result indi-
cates the specific effect of DsbB activity upon production 
and glycosylation of the target disulphide bond-contain-
ing proteins.
Table 2 summarises the comparative growth and volu-
metric production (recombinant protein titre) in wild-
type and ΔdsbB strains producing model glycoproteins. 
Reduction in cell growth was observed when scFv13R4 
and scFv13R4CM were produced in ΔdsbB relative to 
the wt strain. The reduction in cell growth along with 
protein production per cell (protein yield mg/g DCW) 
results in lower scFv13R4 and scFv13R4CM protein 
titres (Fig. 6A, B; Table 2). In contrast, both wild-type and 
ΔdsbB strains expressing RNase A showed similar growth 
(Table  2). Therefore, the observed reduction in RNase 
A protein titre (Table  2) was predominately impacted 
by the decrease in protein per cell (yield) (Fig.  6C, D). 
Fig. 6 Glycosylation of disulphide bond-containing proteins in oxidoreductase mutant (ΔdsbB) of E. coli. Quantitative Western blot analysis 
(densitometry) of A scFv13R4, B scFv13R4CM, C RNase A and D control non-disulphide bond-containing protein NGRP expressed in periplasmic of 
glyco-competent E. coli wild-type (wt) or ΔdsbB strain. Total proteins (A–D) were quantified using pre-determined purified scFv13R4CM, RNase A, or 
NGRP standard curve (5 ng to 100 ng). The data were converted into yield mg/g of dry cell weight (DCW) based on normalisation and calculation 
with measured  OD600 of the samples Glycosylated (yellow bar) and non-glycosylated (green bar) protein as shown (left y-axis). % Glycosylation (% 
 G1/G0 +  G1) is indicated (black circle, right y-axis). Additional file 1: Figure S16, A and B showed representative Western blot images for scFv13R4CM 
and RNase A produced in wt and ΔdsbB strains. Representative Western blot image for NGRP and scFv13R4 have been shown before in Figs. 3B, C, 
and 4B, C. Statistical analysis was conducted by unpaired t-test with Welch’s correction to control sample expressed in wt strain (P < 0.05*, < 0.01**, 
for % glycosylation; P < 0.05◊, < 0.01◊◊, < 0.0001◊◊◊◊, for total protein mg/g DCW). All data were processed from three biological replicates. Error 
bars indicate standard deviation from mean values
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No difference in the cell growth was observed between 
wild-type and ΔdsbB expressing non-disulphide bond-
containing protein NGRP as well as the protein titre pro-
duced between both strains.
Supplementation with chemical oxidant (cystine) improves 
production of disulphide bond‑containing glycoproteins 
in the ΔdsbB strain
The above analysis shows that producing disulphide 
bond-containing proteins in the absence of DsbB 
reduces recombinant protein production (yield and 
titre) and cell growth. Thus, we investigated if supple-
mentation with a small molecule oxidant (e.g. cystine) 
could maintain enhanced glycosylation efficiency but 
also recover the total target protein production levels 
and cell growth in the ΔdsbB strain. Moreover, alter-
native oxidants may provide different rates of modula-
tion for disulphide-bond formation and protein folding 
compared to DsbAB enzymes. In this way glycosylation 
efficiency could be improved without heavily sacrificing 
protein production levels. To perform this experiment, 
wild-type (wt) and ΔdsbB strains of glyco-competent E. 
coli were prepared as before, but now 100  μM of cys-
tine was added into the culture medium along with 
inducers (“Methods” section). Total production levels 
for all disulphide bond-containing proteins increased 
in the ΔdsbB strain upon supplementation with cys-
tine (scFv13R4 2.0-fold, from 1.2 ± 0.2 to 2.4 ± 0.1 mg/g 
DCW, P = 9.6 ×  10–4; scFv13R4CM 2.1-fold, from 
1.3 ± 0.2 to 2.7 ± 0.6  mg/g DCW, P = 0.047; RNase 
A 5.0-fold, from 0.78 ± 0.11 to 3.4 ± 0.8  mg/g DCW, 
P = 1.4 ×  10–5) (Fig.  7A–C). In addition, glycosylation 
efficiency was almost identical with and without cystine 
treatment even though increased protein yields were 
observed (average glycosylation efficiency ± cystine 
treatment; scFv13R4 ΔdsbB = 80 ± 2%, scFv13R4CM 
ΔdsbB = 74 ± 4%, RNase A ΔdsbB = 12 ± 3%) (Fig. 7A–
C). Therefore, resulting in an increase in the absolute 
amounts of glycoprotein under this treatment. The 
scFv13R4 produced in ΔdsbB strain was also evalu-
ated for the binding activity against its cognate anti-
gen β-galactosidase (“Methods” section). The result 
showed increased specific binding activity of scFv13R4 
from the ΔdsbB strain compared to that produced in 
the wild-type strain (ΔdsbB 0 cys = 1.8-fold, ΔdsbB 
100 cys = 1.4-fold) (Additional file 1: Figure S17). It has 
been reported previously that in  vitro glycosylation of 
scFv13R4 with Cj heptasaccharide does not affect pro-
tein activity [92]. However, glycosylation enhanced 
activity of another exemplar single chain Fv (murine 
3D5 scFv) when produced in vivo (in glyco-competent 
E. coli), has been reported [72]. As such, this present 
analysis is consistent and indicates enhanced activity of 
the scFv13R4 glycoconjugate when produced via in vivo 
glycosylation.
Cystine function appears to be redundant in the pres-
ence of DsbAB, as there was no improvement in the pro-
duction of disulphide bond-containing proteins in the 
wild-type strain (Fig.  7A–C). While RNase A produc-
tion in ΔdsbB strain was considerably improved by cys-
tine supplementation, glycosylation in this strain was still 
negatively affected relative to the wild-type (glycosylation 
efficiency wt = 27 ± 5%, ΔdsbB = 12 ± 3%) (Fig.  7C). No 
difference in NGRP production and glycosylation were 
observed when produced in ΔdsbB strain with or without 
cystine (average yield = 5.2 ± 0.5 mg/g DCW, average gly-
cosylation efficiency = 45 ± 4%) (Fig. 7D). The result con-
firmed the specific effect of cystine treatment only upon 
disulphide bond-containing proteins.
In addition to improvement in total protein yield and 
absolute amounts of glycoprotein, cystine treatment 
also produced a better growth phenotype for the ΔdsbB 
strain producing disulphide bond-containing proteins, 
while the growth level was not fully restored to the level 
observed for the untreated wild-type (Table 3). Improve-
ment in protein production per cell (yield) and cell 
growth resulted in increasing disulphide-bond protein 
titre produced in ΔdsbB strain under cystine treatment 
(Table  3). The wild-type strain expressing disulphide 
bond-containing proteins grew similarly with or without 
cystine supplementation (Table 3). Further, cystine addi-
tion appeared to have no impact upon the growth of the 
Table 2 Comparative cell growth and volumetric production 
(protein titre) during recombinant disulphide-bond protein 
production in the wild-type (wt) and ΔdsbB strain
a Final cell density was measured as  Abs600 recorded 4 h after induction
b Total protein titre was determined from the Western blot quantification data 
(glycosylated and non-glycosylated), normalised and converted from sample 
 OD600 of periplasmic fraction and sample volume for Western blot. For the final 
cell density and protein titre, the average of three biological replicates is shown 
and the errors indicate standard deviation. Cell culture was performed under 
standard cultivation condition in shake flask 10:50 ml. The change (increasing or 
decreasing) of cell growth and protein titre relative to control (production in wt 
strain) was analysed by t-test with Welch’s correction (Additional file 2: Table S4)
Proteins Cell  growtha and protein  titreb
Strains
Wild-type (wt) ΔdsbB
scFv13R4 5.04 ± 0.14 3.27 ± 0.08
6.25 ± 0.73 mg/L 1.16 ± 0.42 mg/L
scFv13R4CM 5.40 ± 0.20 3.68 ± 0.00
9.48 ± 1.00 mg/L 3.50 ± 0.23 mg/L
RNase A 2.96 ± 0.08 3.05 ± 0.05
3.15 ± 0.14 mg/L 0.26 ± 0.06 mg/L
NGRP 4.43 ± 0.06 4.43 ± 0.11
13.11 ± 2.25 mg/L 11.12 ± 1.93 mg/L
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ΔdsbB strain producing non-disulphide bond-containing 
protein NGRP and the protein titre was produced simi-
larly (Table  3). These data indicate that stable produc-
tion of recombinant disulphide bond-containing proteins 
is responsible for the growth improvement exhibited in 
ΔdsbB strain, rather than a more global impact upon cell 
redox state due to the absence of DsbB.
It is worthy of mention that we also noticed a differ-
ence in glycosylation efficiency improvement among 
disulphide bond-containing proteins during the expres-
sion in the ΔdsbB strain compared to the produc-
tion under oxygen-depleted conditions. The increase 
in glycosylation efficiency of scFv13R4CM in ΔdsbB 
strain relative to wt strain was higher (up to 1.6-fold) 
(Figs.  6B and 7B) than compared to production under 
low oxygen transfer conditions (25/50 vs. 5/50 flask to 
culture vol ratio) (1.3-fold) (Fig.  5B). Both conditions 
gave a similar improvement in glycosylation efficiency 
for scFv13R4 (1.2- to 1.3-fold) (Figs. 5A, 6A, 7A). While 
glycosylation efficiency of RNase A was enhanced 
during low oxygen transfer (1.7-fold) (Fig.  5C) and 
hypoxic growth/low oxygen level (1.3-fold) (Fig.  5G). 
It is unclear why RNase A glycosylation was negatively 
affected during expression in ΔdsbB, even more con-
sidering the expression level was also greatly reduced 
(Figs.  6C and 7C). We speculate that without DsbAB 
assistance, RNase A forms an intermediate conforma-
tion which has reduced interaction with OTase. Differ-
ent strategies to enhance glycosylation may be required 
to optimise folding-dependent glycosylation of RNase 
A in vivo.
Production of RNase A in the absence of disulphide‑bond 
isomerase (ΔdsbC) improves glycosylation efficiency
Cystine supplementation was shown to increase the pro-
duction of RNase A in a ΔdsbB strain of E. coli (yield 
and titre) (Fig.  7C). However, glycosylation efficiency 
remained low compared with production in the wild-type 
strain. Due to the presence of non-consecutive disul-
phides, RNase A is more likely to be sensitive to incor-
rect pairing during its folding in the periplasm [90, 93]. 
In the periplasm, mispaired disulphide-bonds are rec-
ognised by the disulphide-bond isomerase DsbC, which 
catalyses reshuffling reactions of the mispaired bonds 
Fig. 7 Impact of cystine supplementation upon glycosylation of recombinant proteins in ΔdsbB strain and glycosylation of RNase A in 
disulphide-bond isomerase mutant (ΔdsbC). (A-D) Quantitative Western blot analysis (densitometry) of A scFv13R4, B scFv13R4CM, C RNase A 
and D NGRP non-disulphide control protein produced in the periplasm of glyco-competent E. coli wild-type (wt) or ΔdsbB strain supplemented 
with or without 100 μM cystine during protein expression. E, F Quantitative Western blot analysis (densitometry) of E RNase A and F control 
non-disulphide bond-containing protein NGRP expressed in periplasmic of glyco-competent E. coli ΔdsbC. Total proteins (A–F) were quantified 
using pre-determined purified scFv13R4CM, RNase, or NGRP standard curve (5 ng to 100 ng). The data were converted into mg/g of dry cell weight 
(DCW) based on normalisation and calculation with measured  OD600 of the samples. Glycosylated (yellow bar) and non-glycosylated (green bar) 
protein as shown (left y-axis). % Glycosylation (%  G1/G0 +  G1) is indicated (black circle, right y-axis). Statistical analysis was conducted by unpaired 
t-test with Welch’s correction to control sample expressed in wt or ΔdsbB strain without cystine treatment (A–D) or to control sample expressed 
in wt strain (E, F) (P < 0.05*, < 0.01**, for % glycosylation; P < 0.05◊, < 0.001◊◊◊, for normalised total protein). All data were processed from three 
biological replicates. Error bars indicate standard deviation from mean values
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[90, 94]. Previously, Kowarik et al. demonstrated in vitro 
that rapid oxidation of RNase A generated mixed disul-
phide isoforms as preferable substrates for bacterial 
OTase (PglB) [23]. Another in vitro study showed the for-
mation of intermediate disulphide isoforms were domi-
nantly observed within RNase A in the absence of DsbC 
[93]. Indeed, the activity of the oxidoreductase subunit in 
some eukaryotic OTases leads to transient mixed disul-
phide forms of the target proteins, promoting an inter-
mediate folding state, and consequently increasing their 
window for glycosylation [71, 95].
To investigate if RNase A glycosylation could be 
improved in the same way in  vivo (in bacteria) by 
attempting to increase intermediate mixed disulphide 
forms, protein production was performed in a ΔdsbC 
strain of glyco-competent E. coli. Analysis of the periplas-
mic fraction showed increasing glycosylation efficiency 
of RNase A produced in ΔdsbC (29% to 53%, P = 0.001) 
(Fig.  7E). Total protein was also higher compared with 
production in the wt strain (1.4-fold, from 3.1 ± 0.3 to 
4.3 ± 0.5 mg/g DCW, P = 0.042) (Fig. 7E). NGRP produc-
tion and glycosylation was similar in both wt and ΔdsbC 
strain (protein = 4.4 ± 0.6  mg/g DCW, % glycosyla-
tion = 48 ± 3%) indicating no effect upon the non-disul-
phide bond-containing protein (Fig.  7F). Production of 
scFv13R4 and scFv13R4CM in the ΔdsbC strain resulted 
in compromised protein production levels (scFv13R4, 
1.6-fold, from 4.8 ± 0.4 to 2.9 ± 0.3 mg/g DCW, P = 0.004; 
scFv13R4CM, 1.2-fold, from 4.8 ± 0.1 to 4.1 ± 0.4  mg/g 
DCW), and minor decreases in protein glycosylation effi-
ciency (scFv13R4, from 70 to 65%; scFv13R4CM, from 49 
to 39%, P = 0.002) (Additional file  1: Figure S18). While 
the isomerase activity is not necessary for proteins with 
only single disulphide-bonds or those possessing consec-
utive disulphide-bonds, it has been reported that DsbC 
displays a chaperone function to improve stability and 
solubility of various scFv model proteins [96–98].
To confirm that RNase A produced in ΔdsbC strain 
increases production of intermediate folding form of 
RNase, we analysed the activity of RNase produced from 
this strain (“Methods” section). A recent study reported 
that glycosylation of RNase A produced in glyco-compe-
tent E. coli had a similar activity with its non-glycosylated 
version [99]. Therefore, any decrease in the activity of 
RNase A could be associated with the increased pres-
ence of pre-folded intermediate forms. As we expected, 
the activity assay showed 3.3-fold reduction of RNase A 
produced in the periplasm of ΔdsbC compared to the one 
produced in the wt strain (Additional file 1: Figure S19). 
Going forward, protein folding modulation strategies 
could be coordinated (e.g., by titrating the expression or 
activity of folding modulators) to increase glycoprotein 
yield, glycosylation and to retain biological activity.
Surprisingly, the ΔdsbC strain expressing RNase A 
grew better than the wt strain expressing the same pro-
tein which also resulted in increased recombinant pro-
tein titre (Table 4). Both wild-type and ΔdsbC expressing 
NGRP showed little or no difference in the cell growth 
and protein titre (Table  4). We also observed that the 
expression of scFv13R4 but not the CM variant in the 
ΔdsbC strain negatively impacted cell growth, and con-
sequently the recombinant protein titre (Additional file 2: 
Table 3 Comparative cell growth and volumetric production (protein titre) during recombinant disulphide-bond protein production 
in the wild-type (wt) and ΔdsbB strain supplemented with small molecule oxidant (cystine)
a Final cell density was measured as  Abs600 recorded 4 h after induction
b Total protein titre was determined from the Western blot quantification data (glycosylated and non-glycosylated), normalised and converted from sample  OD600 of 
periplasmic fraction and sample volume for Western blot. For the final cell density and protein titre, the average of three biological replicates is shown and the errors 
indicate standard deviation. cell culture was grown under standard cultivation condition in shake flask 10:50 ml
c Culture medium was added with or without 100 μM of cystine at the same time with inducers addition. n.d. not determined. The change (increasing or decreasing) 
of cell growth and protein titre relative to control (production in wt or ΔdsbB strain without cystine supplementation) was analysed by t-test with Welch’s correction 
(Additional file 2: Table S5)
Proteins Cell  growtha and protein titre
Wild-type (wt) ΔdsbB
0  Cysc 100 Cys 0 Cys 100 Cys
scFv13R4 4.88 ± 0.08 4.91 ± 0.20 3.08 ± 0.10 3.50 ± 0.05
5.87 ± 0.21 mg/L 6.89 ± 0.37 mg/L 1.28 ± 0.24 mg/L 2.97 ± 0.14 mg/L
scFv13R4CM 4.45 ± 0.09 4.35 ± 0.09 2.90 ± 0.00 3.65 ± 0.00
6.42 ± 0.70 mg/L 6.15 ± 0.41 mg/L 1.28 ± 0.24 mg/L 3.42 ± 0.81 mg/L
RNase A 3.55 ± 0.05 3.60 ± 0.14 3.12 ± 0.00 3.39 ± 0.05
5.64 ± 1.05 mg/L 5.40 ± 0.36 mg/L 0.85 ± 0.12 mg/L 4.07 ± 0.89 mg/L
NGRP n.d n.d 3.90 ± 0.00 3.83 ± 0.06
6.66 ± 0.77 mg/L 7.46 ± 0.33 mg/L
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Table  S6). Together with the result from glycoprotein 
production in the ΔdsbB strain, we suggest different pro-
teins could be glycosylated more efficiently in vivo based 
upon modulation of their distinct folding requirements 
to place them in a specific unfolded or intermediate form 
for optimal glycosylation.
Discussion
Our initial study with NGRP glycosylation indicated 
that for this particular protein, production levels had 
little impact upon glycosylation efficiency. Availability 
of lipid base, sugar precursor, and glycan conjugating 
enzyme could in principle be limiting factors for glyco-
sylation, for example in the scenario where target pro-
tein production exceeds cell glycosylation capacity [33, 
48, 64, 66, 69]. However, if the enzyme and lipid-glycan 
substrate are not rate limiting and protein glycosylation 
efficiency is observed similarly across different expres-
sion levels, we propose that protein glycosylation in 
this context could depend predominantly upon sequon 
accessibility to the glycosylation enzyme (PglB/oligo-
saccharyltransferase). In this simple way, if the sequon 
is not accessible for glycosylation once target protein 
has folded or diffused away from the membrane, the 
degree of glycosylation will only be dependent upon the 
transient unfolded state or membrane residency time 
during translocation, in which PglB “sees” the sequon 
and not the level of target protein production.
To explore the effect of membrane residency time 
upon protein glycosylation, we monitored the glyco-
sylation state of proteins located in the periplasm and 
inner membrane. Using NGRP and scFv13R4 as the 
model proteins, in which the target protein was trapped 
in the membrane by generating a poorly processed sig-
nal cleavage site (TMT variant) attached to the target 
proteins. Improvement in glycosylation efficiency of 
TMT-scFv13R4, located in the membrane fraction, 
over the wt-scFv13R4 located in the periplasm frac-
tion, seemed to agree with the hypothesis in this study. 
By increasing membrane residency of target protein 
scFv13R4, glycosylation efficiency was improved by up 
to 25–40%. Following extended time in the membrane, 
local interaction of the protein substrate and the OTase 
would likely increase, leading to enhanced glycosylation 
efficiency. However, the effectiveness of this strategy 
seems to be protein specific, as some factors such as 
protein size and structural complexity might also influ-
ence protein folding rate during membrane retention, 
and therefore influence sequon accessibility for glyco-
sylation. For example, NGRP is a small protein with a 
predicted structure consisting of only a single α-helical 
chain (d =  ~ 10–12  Å). For this protein, folding could 
be initiated very early whilst inside the translocon tun-
nel (d =  ~ 20  Å) (Fig.  2A, i) [100, 101]. Previous stud-
ies showed that some proteins with more complex 
architecture and complex tertiary structural modifi-
cations, such as disulphide-bonds, underwent folding 
suppression within the translocon [84, 85]. Moreover, 
for many of these proteins, folding would continue 
for some period after translocation [102–104]. Taken 
together, we assume that simpler proteins like NGRP 
do not experience the same spatial and structural con-
straints as scFv13R4 upon folding in the translocon 
during extended residency time. These constraints sug-
gest that, scFv13R4 is likely to remain unfolded during 
membrane retention, meaning that the sequon remains 
available for glycan addition for a greater length of 
time, resulting in greater interaction with OTase and 
more efficient glycosylation.
We then further investigated if modulation of target 
protein folding could enhance protein glycosylation. By 
monitoring the glycosylation efficiency of model disul-
phide bond-containing proteins, we found that producing 
the protein under suboptimal condition for disulphide-
bond formation could enhance glycosylation efficiency. 
In this experiment, the rate of disulphide-bond synthesis 
was adjusted by varying the oxidants (oxygen, chemical 
oxidants, oxidoreductases DsbAB and DsbC) through 
changing culture conditions and E. coli production strain 
genetic backgrounds. Owing to the structural diversity 
of model disulphide bond-containing proteins, we also 
identified specific environmental and biochemical con-
ditions to optimise glycosylation efficiency of different 
proteins. Sequon location was shown to play a key role 
is deciding which methodology is most likely to result in 
Table 4 Comparative cell growth and volumetric production 
(protein titre) during RNase A production in the wild-type (wt) 
and ΔdsbC strain
a Final cell density was measured as  Abs600 recorded 4 h after induction
b Total protein titre was determined from the Western blot quantification data 
(glycosylated and non-glycosylated), normalised and converted from sample 
 OD600 of periplasmic fraction and sample volume for Western blot. For the 
final cell density and protein titre, the average of three biological replicates is 
shown and the errors indicate standard deviation. Cell culture was grown under 
standard cultivation condition in shake flask 10:50 ml. The change (increasing or 
decreasing) of cell growth and protein titre relative to control (production in wt 
strain) was analysed by t-test with Welch’s correction (Additional file 2: Table S6)




RNase A 2.69 ± 0.05 3.60 ± 0.00
2.94 ± 0.37 mg/L 5.43 ± 0.69 mg/L
NGRP 5.33 ± 0.09 4.96 ± 0.00
7.79 ± 0.42 mg/L 7.95 ± 1.53 mg/L
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improved glycosylation efficiency. If the sequon is located 
around highly structured regions this can lead to reduced 
glycosylation efficiency, as shown previously [23, 71, 105, 
106]. For example, we show that when located near resi-
dues involved in disulphide-bond formation, the sequon 
is less well glycosylated by PglB. For scFv13R4CM where 
the sequon is proximal to these regions, expression in 
the ΔdsbB strain may provide an extension in the time 
required for disulphide-formation, therefore increasing 
the sequon exposure for glycan transfer by PglB, leading 
to ~ 1.6-fold (from ~ 50% to 80%) enhanced glycosyla-
tion efficiency (Figs.  6B and 7B). In another example, 
RNase A glycosylation efficiency was improved ~ 1.9-fold 
(from ~ 28% to 53%) when the protein was produced in a 
ΔdsbC strain (Fig. 7E). As a protein with multiple disul-
phides, RNase A production in the ΔdsbC strain may fold 
into a specific intermediate form, leading to the sequon 
becoming more accessible for PglB compared to the one 
produced in ΔdsbB or under oxygen-depleted conditions. 
Lastly, scFv13R4 glycosylation efficiency was observed 
to be less sensitive, and displayed relatively similar levels 
across all the different disulphide attenuation treatments 
(1.2- to 1.3-fold or from ~ 65% to 80%). Having a distal 
location from cysteine residues, the availability of the R4 
sequon may be less influenced by disulphide-bond for-
mation and hence a limited effect upon interaction with 
PglB.
Production of disulphide bond-containing glycopro-
teins under these suboptimal conditions required for 
their folding could be problematic in terms of achieving 
high glycoprotein yields and titres. Indeed, cell growth 
was dramatically reduced during cultivation in oxygen-
depleted conditions, possibly due to general metabolic 
burden caused by oxygen limitation. On the other hand, 
fitness issues during protein production in the ΔdsbB 
strain seemed to be related to protein specific stress 
conditions, since strains producing the control protein 
NGRP grew similarly under these conditions. While 
increased glycosylation efficiency was observed during 
the production of disulphide-bond containing protein 
RNase A in the ΔdsbC strain, the produced proteins were 
shown to be less active. Total production of disulphide 
bond-containing proteins was reduced 50–90% when 
expressed in the ΔdsbB strain. However, supplementa-
tion with the chemical oxidant cystine, was shown to 
rescue protein yield and cell viability whilst maintaining 
glycosylation efficiency of the ΔdsbB strain, therefore 
increasing protein titre and the absolute amount of gly-
coprotein produced. This result indicated the potential 
for using different oxidants or to tune expression levels of 
the native oxidoreductase to modulate folding-depend-
ent glycosylation of target proteins and to balance with 
host cell physiology. To further optimise the strategy, 
improvement in total protein production, glycosylation 
efficiency, protein activity, and the effect upon the cell 
growth need to be considered. Therefore, those studies 
will be informative for the selection of strains, medium, 
cultivation conditions, and bioprocess design for gly-
coprotein production. This includes options to separate 
biomass production and target protein expression to 
avoid the physiological burden of unfolded protein stress 
during cell growth and to improve volumetric production 
(protein titre). However, it is also worthy of mention that 
for some production strategies, that enhanced glycosyla-
tion efficiency can be a main consideration, especially if 
protein purity is essential and the downstream protein 
purification step can be a bottleneck [48]. Moreover, if 
the amount of protein needed for an application is rather 
low, for example for use as a glycoconjugate vaccine (25–
100  μg needed per vaccination), improved glycosylation 
efficiency may compensate for the reduction in total pro-
tein production titres [48].
As the use of different folding attenuation conditions 
to produce the model proteins in this study showed dif-
ferent pros and cons in terms of protein glycosylation 
efficiency, yields, and cell growth. The production strat-
egy could also be prioritised dependent on the ultimate 
application and the requirement for maximising the 
total amount of glycoprotein (titre) vs. maximising the 
proportion of glycosylated product (glycosylation effi-
ciency). The highest glycoprotein titre of the scFv model 
proteins used here tended to be achieved by production 
in the wild-type strain and under more oxygenated con-
ditions (Fig. 8A, B). On the other hand, for production 
of scFv13R4 and scFv13R4CM, enhanced glycosylation 
efficiency was obtained by production in the ΔdsbB 
strain, in which improved titre could be achieved by cys-
tine supplementation during the cultivation (Fig. 8A, B). 
Production of RNase A in the ΔdsbC strain resulted in 
increased glycosylation efficiency and glycoprotein titre, 
while at cost of reduced protein activity (Fig.  8C, and 
Additional file 1: Figure S19). Future study could explore 
how optimisation of folding modulators could benefit 
glycosylation efficiency, glycoprotein titre, and main-
tain biological activity of the product. Production of 
glycosylated NGRP in terms of glycosylation efficiency 
seemed to give similar results irrespective of produc-
tion in the wild-type or oxidoreductase strains (Fig. 8D). 
The optimised condition for production of glycosylated 
NGRP was flask cultivation at a 10/50 culture to flask 
volume ratio, which gave improvement both in glyco-
protein titre and glycosylation efficiency, regardless the 
type of producer strains (wt/ΔdsbB/ΔdsbC) (Fig. 8D). It 
is worthy of mention that increased NGRP glycoprotein 
yield and titre was achieved at higher induction expres-
sion (200  μM PPDA at the experiment in the Fig.  6D 
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compared to 40  μM PPDA in any other experiments, 
“Methods” section) without significantly affecting glyco-
sylation efficiency (Fig. 8D).
The final steps of protein translocation through the 
secretion machinery and subsequent folding could be 
viewed as a competing reaction with glycosylation, since 
the sequon will potentially be less available for glycan 
transfer upon target protein folding. In eukaryotic cells 
and the bacterium C. jejuni, glycosylation is coordinated 
temporally and spatially with protein translocation and 
folding pathways to increase glycosylation efficiency, and 
further has been mechanistically demonstrated in higher 
eukaryotic (mammalian) cells [22, 26]. This is demon-
strated by coupling of transmembrane OTase activities 
with Sec translocation. The subunits of some eukaryotic 
heteroligomeric Otases possess oxidoreductase activity 
which interfere with disulphide-bond formation of the 
target proteins, leading to formation of transient inter-
mediate protein conformations more accessible for gly-
cosylation [71, 95]. However, expression of heterologous 
glycosylation machinery in E. coli, such as the pgl path-
way from C. jejuni, appears to be uncoordinated and less 
efficient at protein glycosylation than in the native host. 
One explanation for this reduced glycosylation efficiency 
of the heterologous host is the potential lack of accessory 
proteins for modulating the translocation process and 
protein folding environment thereby affecting target pro-
tein sequon accessibility for the OTase [26]. Informed by 
glycosylation events in the native system, efforts to mod-
ulate sequon interaction with PglB could be a potential 
approach to optimise glycoprotein production in E. coli, 
the global aim of this present study.
Based on the general principle of folding-dependent 
glycosylation, the strategy performed here could be 
Fig. 8 Summary of glycosylation efficiency (%) and glycoprotein titre (mg/L of glycosylated protein) of A scFv13R4, B scFv13R4CM, C RNase 
A, and D NGRP during production in glyco-competent E. coli K-12 by use of different cultivation conditions to modulate target protein folding. 
Glycoprotein titres were converted from the yield (mg/g DCW), cell growth, and total protein titre results given in the Figs. 5, 6, 7, and Tables 1, 2, 
3, 4 and Additional file 2: Table S6 (“Methods” section). Colour symbols indicate the experiment or figure/table sources for the data (Fig; 1 = Table 1, 
2 = Table 2, 3 = Table 3, 4 = Table 4, 5 = Additional file 2: Table S6). A similar wt and ΔdsbB cultivation were run in four different batches of experiment, 
which were (i) wt oxygen transfer experiment (10/50, Fig. 5A–D), (ii) wt against oxidoreductase knockout ΔdsbB (Fig. 6A–D), (iii) wt and ΔdsbB 0 
cystine treatment (Fig. 7A–D), (iv) wt against oxidoreductase knockout ΔdsbC (Fig. 7E, F, Additional file 1: Figure S18A, B). A variation of inducer 
concentration for NGRP expression was used in the experiment of Fig. 6D (200 μM instead of 40 μM PPDA, “Methods” section)
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similarly adopted by using specific conditions for the 
production of non-disulphide bond-containing proteins. 
Recently, DeLisa and co-workers [92] demonstrated the 
versatility of cell-free glycoprotein production systems 
for rapid screening of functional Otases and glycosyl-
transferases from different bacteria and eukaryotes. 
Due to the open nature and modularity of this plat-
form, screening could be rapidly and simply expanded 
using collections of chaperones and folding catalysts to 
improve glycosylation of new target proteins. Incorporat-
ing native or engineered chaperone candidates from E. 
coli or even C. jejuni may lead to identification of acces-
sory proteins promoting more efficient protein glycosyla-
tion [107–110]. Moreover, the rapid characterisation of 
folding modulator-target protein combinations in  vitro 
would allow early validation before further optimisation 
in vivo.
Lastly, the study presented here also may also show the 
potential of increasing membrane residency time of the 
target protein during Sec translocation to enhance gly-
cosylation efficiency. While this study provides a proof 
of concept for this strategy, the use of uncleaved signal 
peptide would provide practical challenges in the down-
stream process of protein production, such as membrane 
purification and signal peptide removal. For further 
work, the use of alternative protein delivery mechanisms 
to the periplasm via the signal recognition particle (SRP) 
pathway may provide further opportunities to coordinate 
translation, translocation and glycosylation [24]. Since 
translocation occurs co-translationally via the SRP, modi-
fying codon usage of the gene encoding the target pro-
tein could be used to influence transport rate [111], and 
hence glycosylation efficiency.
Conclusion
In this study, we demonstrated that improved glycosyla-
tion efficiency in the heterologous host could be achieved 
by mimicking the coordination between protein trans-
location, folding and glycosylation observed in native 
such as Campylobacter jejuni and mammalian hosts. 
Furthermore, it provides insight into strain engineering 
and bioprocess strategies, to improve glycoprotein yield, 
titre and to avoid physiological burden of unfolded pro-
tein stress to cell growth. In addition to existing strate-
gies to enhance protein glycosylation in E. coli, the work 
presented here provides new approaches that can be used 
in order to develop more robust recombinant glycoengi-
neering platforms.
Methods
Strains, plasmids, and general growth conditions
Cloning strains: E. coli NEB5α (NEB). Expression strain: 
E. coli Top10F’ (Thermo Fisher); E. coli K-12 wild -type 
(wt), dsbB::kan (ΔdsbB) and dsbC::kan (ΔdsbC) with 
inactivated dsbB or dsbC due to insertion of a kanamy-
cin-resistance gene were used as indicated (Keio col-
lection) [112]. Plasmids: Four genes encoding target 
proteins; Cj0114 NGRP, anti-β-galactosidase single-chain 
Fv scFv13R4 and R4CM, and bovine pancreatic ribonu-
clease RNase A, all modified with N-terminal PelB sig-
nal peptide, C-terminal hexahistidine  (His6) tag, and 
single bacterial glycosylation sequon were synthesised 
by gBlocks (Integrated DNA Technologies). The genes 
were subcloned into ampicillin resistance determinant-
containing pDEST-ORS expression vector [76]. Chloram-
phenicol resistance determinant-containing pACYC184 
plasmid carrying the entire C. jejuni pgl locus (pACYC 
pgl) [15] was transformed into the expression strain to 
allow glycoprotein production (glyco-competent). Gen-
eral growth conditions: E. coli NEB5α strains were rou-
tinely grown in LB medium (0.5% yeast extract, 0.5% 
NaCl, 1.0% Bactotryptone) to enrich constructed plas-
mids. For glycoprotein production studies, expression 
strains of E. coli were grown in LB medium as starter cul-
tures and in TB medium (2.7% yeast extract, 4.5% glyc-
erol, 1.3% Bactotryptone) with 0.2% glucose for protein 
expression. All media were supplemented with antibiot-
ics as required (ampicillin 100 μg/ml, kanamycin 50 μg/
ml, and chloramphenicol 25  μg/ml). Protein expression 
was induced by the addition of IPTG (Isopropyl β-d-
1-thiogalactopyranoside) and PPDA (Pyrimido [4,5-d] 
pyrimidine-2,4-diamine) as indicated.
In silico analysis of protein structure and translocation
Homology modelling of NGRP, scFv13R4, and 
scFv13R4CM was performed using Phyre2 (protein 
homology/analogy recognition engine) [113]. Ribbon 
models were drawn by UCSF Chimera [114]. Signal pep-
tide profile and protein translocation of NGRP/scFv13R4 
wt and TMT were predicted using SignalP4.1 [81].
PCR site‑directed mutagenesis
Primers used to generate mutant versions of the PelB 
cleavage site (TMT) are listed in Additional file  2: 
Table  S1 and were supplied by Integrated DNA Tech-
nologies. Inserts NGRP or scFv13R4 and linearised 
plasmid (backbone) pDEST-ORS-PelB TMT mutant 
were generated from the template pDEST-ORS-PelB wt 
NGRP or scFv13R4 by PCR: 98  °C for 30 s; 35 cycles of 
10  s at 98  °C, 30  s at the primer annealing temperature 
(gradient), and extension at  72oCfor 30  s per 1 kb; with 
a final extension step of 72 °C for 10 min. PCR products 
were treated with DpnI (NEB) and purified using a gel 
extraction kit (Qiagen). Insert NGRP or scFv13R4 was 
assembled into backbone pDEST-ORS-PelB TMT fol-
lowing NEB builder Hi-fi mix protocol (NEB) to create 
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pDEST-ORS-NGRP/scFv13R4 TMT. Plasmid products 
were cloned into E. coli NEB5α and isolated by miniprep 
according to the manufacturers (Qiagen) protocol. All 
constructs were confirmed by DNA sequencing.
Growth conditions for glycoprotein production
To prepare inocula for glycoprotein production tests, 
expression strains of E. coli bearing pACYC pgl (glyco-
competent) were transformed with pDEST-ORS con-
structs specific for each target protein. Freshly plated 
colony transformants were picked and grown overnight 
(37 °C, 200 rpm) in LB medium supplemented with anti-
biotics. The starter culture then was transferred (1% 
v/v) into TB medium (with added glucose and antibi-
otics) in a shake flask and grown to  OD600 = 0.6 (37  °C, 
200  rpm). At this point, cells were induced with IPTG 
(100 μM) and PPDA (0–400 μM or 0–200 μM for titra-
tion assay; 400  μM during membrane residency test of 
wt and TMT variant; 40  μM for NGRP during expres-
sion in oxygen-depleted conditions, in ΔdsbC strain, and 
in ΔdsbB strain with cystine supplementation; 200  μM 
for NGRP during expression in ΔdsbB strain; 0  μM for 
scFv13R4 and scFv13R4CM, and 200  μM for RNase A 
in all conditions for redox attenuation experiment) and 
then divided into three for different cultivation strategies. 
Microculture: 1 ml of cultures in 96-well deep well plate, 
37 °C 1000 rpm for 3 h (titration assay) or 6 h (membrane 
residency test of wt and TMT variant). Shake flask: 10 ml 
(standard condition) or 5, 10 and 25 ml (treatment condi-
tions, as indicated) of culture in 50 ml shake flask, 37 °C 
200  rpm for 4  h or 6  h (titration assay of wt and TMT 
variant only). 6-well: 5  ml of cultures in 6-well plate, 
incubated in a Don Whitley VA500 microaerobic cabinet 
set to 3% or 15%  O2, 37 °C 100 rpm for 4 h.
Cell fractionation
Cell fractionation was performed from the final culture 
of glycoprotein production experiments after the speci-
fied time post-induction. Cultures were normalised to 
the same ODV 1–5  (OD600 x ml = 1–5) to collects peri-
plasmic and membrane fractions. The cultures with 
specific ODV were centrifuged (17,000g, 4  °C, 1  min) 
and cell pellets resuspended in 250 µl Buffer 1 (500 mM 
Sucrose, 5 mM EDTA, 100 mM Tris–acetate pH 8.2), fol-
lowed by addition of lysozyme (0.16 mg/ml) and Milli-Q 
water (250 μl). Cells were incubated on ice for 5 min, and 
10 µl of 1  M  MgSO4 added to stabilise the spheroplast. 
Periplasm (supernatant) was collected from spheroplast 
(pellet) by centrifugation (17,000g, 4 °C, 10 min). To pro-
duce membrane fractions, spheroplasts were washed 
with 500 µl Buffer 2 (250  mM sucrose, 10  mM  MgSO4, 
50  mM Tris–acetate pH 8.2), resuspended in 500 µl 
Buffer 3 (2.5 mM EDTA, 0.1% sodium deoxycholate, 2U 
benzonase, 50 mM Tris–acetate pH 8.2), and stored over-
night at − 80  °C. The following day, spheroplasts were 
lysed by freeze-thawing and cytoplasm (supernatant) and 
membrane fractions (pellet) separated by centrifugation 
(17,000g, 4 °C, 30 min). Pellets were washed with 500 μl 
Buffer 3 and resuspended in 500 μl of Buffer 3 + SDS (1%) 
to obtain the membrane fraction.
Western blot analysis
The amount of glycoprotein produced in periplasmic 
and membrane fractions was analysed by Western blot. 
Samples were resuspended in SDS-PAGE loading buffer 
(ThermoFisher), supplemented with 75  mM dithi-
othreitol, and boiled for 10 min. Equal amounts of sam-
ple were separated by SDS PAGE (Biorad) and Western 
blotted onto PVDF 0.2  µM pore size membrane using 
a Turbo Transblot apparatus (Biorad). The membrane 
was blocked with 5% (w/v) milk powder in PBS (30 min, 
50  rpm shaking, room temperature). Membranes were 
incubated overnight (50  rpm, 4  °C) with mouse mono-
clonal anti-His antibody (1:3000 dilution in PBS 5% milk, 
Pierce) and rabbit polyclonal anti-Cj glycan (CjNgp) pri-
mary antibody(1:500 dilution in PBS 5% milk) as appro-
priate. Membranes were washed three times with PBS, 
followed by incubation with anti-mouse and anti-rabbit 
secondary antibody (1:30,000 dilution in PBS 5%, Li-Cor) 
(50 rpm, in the dark at room temperature, 30 min), and 
then washed three times with PBS. The protein bands 
were visualised with a Li-Cor Odyssey scanner. Proteins 
were quantified based on densitometry analysis using Li-
Cor Image Studio 5.0. Pre-determined purified protein 
from each sample (scFv13R4, RNase A, or NGRP) was 
used as a standard for quantification (5 ng to 100 ng). All 
data were produced in biological triplicate.
Data processing and statistical analysis
Data were processed and analysed using Microsoft Excel 
and GraphPad Prism9. Each data point was the average 
from three biological replicates, and error bars show 
calculated standard deviation. For Western blot quan-
tification, protein samples were measured from each 
biological replicate of isolated cell fraction (periplas-
mic or membrane). Additional file  1: Figure S20 shows 
a representative Western blots images for blot repro-
ducibility of PelB 2-NGRP (representative from Fig. 3C) 
expressed in periplasmic fraction from three biological 
replicates. A standard curve was constructed from pre-
determined purified protein (scFv13R4, RNase A, or 
NGRP: 5–100 ng), and used to calibrate Western blot sig-
nal intensity of protein samples. The data was fitted with 
linear regression, and the linear equation from the stand-
ard curve was used to normalise and convert the signal 
into ng of the protein. Representative standard curve for 
Page 22 of 25Pratama et al. Microb Cell Fact          (2021) 20:198 
NGRP and the use of standard curve for protein quantifi-
cation are shown in Additional file 1: Figure S21. Conver-
sion of protein quantification data into the yield mg/g of 
dry cell weight (DCW) based on normalisation and cal-
culation from the measured  OD600 of samples. Dry cell 
weight was determined following the previous protocol 
[76], and the conversion factor of 0.35 mg/ml per  OD600 
was acquired. Protein titre mg/l was determined from 
protein quantification data (ng) converted and normal-
ised from  OD600 of collected samples and and volume of 
sample (μl) for Western blot. Statistical analysis was con-
ducted by unpaired t-test with Welch’s correction, and P 
value < 0.05 was considered statistically significant.
scFv13R4 binding assay
scFv13R4 binding activity against its cognate antigen 
β-galactosidase was performed following bio-dot proto-
col [115]. 2  μl of β-galactosidase (0.3  mg/ml) dots were 
spotted onto a nitrocellulose membrane (Amersham 
Hydrobond), and the membrane then left to dry for 
5–15 min. To block non-specific binding site, the mem-
brane was incubated with 5% (w/v) milk powder in PBS 
for 1 h (50 rpm, RT). The membrane then was left to dry 
for 2 h in 40 °C. To prepare binding mix, each 2 μl of pro-
tein sample from isolated periplasmic fraction was added 
onto the dot of β-galactosidase, with 2 μl of protein buffer 
was added instead as a negative control. The membrane 
then left to dry again for 15 min. Afterwards, the mem-
brane was probed with primary (mouse monoclonal anti-
his) and secondary (anti-mouse) antibody to detect the 
scFv13R4 following the similar protocol with the West-
ern blot. The protein dots were visualised with the Li-Cor 
Odyssey scanner and the signal intensity was analysed by 
densitometry using Image Studio 5.0 Software. Specific 
binding activity of was measured by normalising the den-
sitometric signal with the amount of protein sample. All 
data were produced in biological triplicate.
RNase A activity assay
RnaseAlert lab test kit (Invitrogen) was used to assay 
RNase A activity of the protein sample. The reaction 
mix consist of 10 μl of RNase A substrate (20× dilution 
with RNase A buffer solution), 5 μl of protein sample 
from periplasmic fraction (1000×), and 85 μl of nucle-
ase-free water. As a negative control, 5 μl of protein 
buffer or 5 μl of protein sample from periplasmic frac-
tion of non RNase A producer strain was added instead 
into the reaction mix. The reaction mix was transferred 
into 96-well plate, and then incubated in the Clariostar 
plate reader for 1 h 37 °C. The RNase A substrate from 
the kit is a modified RNA nucleotide that emits a green 
fluorescence when it is degraded by RNase. The fluo-
rescence activity of degraded substrate was recorded 
overtime during the incubation (RFU at 490/520  nm). 
RNase A specific activity was quantified by normalising 
the rate of substrate degradation (RFU/minute) with 
the amount of protein sample. All data were produced 
in biological triplicate.
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